Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Strata Critical Medical, Inc.NASDAQ: SRTA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $2.4M, compared with -$3.49M a year earlier. Trailing-twelve-month net income was -$19.83M.
Context
- Net income amounted to 21.0% of revenue in FY2025, up 10.0 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$5.76M (-113.9%) for the fiscal year ending Dec 2026, a slowdown from the +251.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.4M+127.2% QoQ
- Last fiscal yearDec 2025
- $41.35M+251.4% YoY
- LTMMar 2026
- -$19.83M-25.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +168.8% | -52.8% | -221.6 pp |
| 1 year | +251.4% | -113.9% | -365.4 pp |
| 3-year CAGR | — | -33.1% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 41.35M USD
- Year-over-year change
- +251.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.35M | +251.4% |
| FY2024 | 2024-12-31 | (27.31M) | +51.3% |
| FY2023 | 2023-12-31 | (56.08M) | -105.7% |
| FY2022 | 2022-12-31 | (27.26M) | +31.9% |
| FY2021 | 2021-09-30 | (40.05M) | — |
Net Income vs competitors
How SRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -25.4% is the 5th highest of 9, against a peer median of -19.5%.
- Net income amounts to 7.8% of revenue for SRTA, versus a peer median of 8.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | £237.85M GBP | — | — | — | |
| LTM Apr 2026 | $152.56M USD | -282.8% | — | 9.9% | |
| LTM Feb 2026 | $42.63M USD | +6.0% | -3.4% | 10.9% | |
| LTM Mar 2026 | $36.31M USD | -66.3% | — | 19.8% | |
| LTM Mar 2026 | $34.61M USD | -27.3% | -22.7% | 2.6% | |
| LTM Mar 2026 | $33.82M USD | -11.7% | +152.8% | 8.8% | |
| LTM Mar 2026 | $24.9M USD | +29.8% | — | 5.6% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $19.83M USD | -25.4% | — | 7.8% |
| LTM Mar 2026 | $17.58M USD | — | -45.6% | 20.0% | |
| LTM Mar 2026 | $14.99M USD | -33.6% | -22.7% | 1.8% | |
| LTM Mar 2026 | $9.43M USD | +214.4% | — | 1.1% | |
| Peer median (excluding SRTA) | — | -19.5% | -22.7% | 8.8% | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | 41.35M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 8.19M |
| Deferred Income Tax | (3.64M) | (772K) | (1.47M) | (255K) | 432K |
| Stock-Based Compensation | 9.62M | 8.28M | 12.5M | 19.89M | 17.83M |
| Change in Working Capital | (2.2M) | (17K) | (6.74M) | (3.01M) | (9.08M) |
| Accounts Receivables | (414K) | (5.35M) | (10.25M) | (998K) | (12.03M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 9.9M | 0 | 0 | 0 |
| Other Working Capital | (1.79M) | (4.57M) | 3.52M | (2.01M) | 2.95M |
| Other Non-Cash Items | 20.06M | (23.08M) | 12.32M | 2.2M | (107.63M) |
| Operating Cash Flow | (15.62M) | (37.13M) | (32.35M) | (2.52M) | (48.91M) |
| Capital Expenditures | (801K) | (730K) | (2.11M) | (32.99M) | (11.01M) |
| Acquisitions (Net) | (23.07M) | (48.1M) | (39K) | (2.23M) | (69.35M) |
| Purchases of Investments | (308.77M) | (228.21M) | (265.97M) | (143.26M) | (146.26M) |
| Sales of Investments | 11.3M | 356.38M | 285.07M | 177.45M | 296.36M |
| Other Investing Activities | (504K) | 0 | 138K | (2.11M) | (1.42M) |
| Investing Cash Flow | (321.34M) | 79.34M | 17.09M | (1.02M) | 69.75M |
| Debt Repayment | (1.17M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 119.63M | 87K | 0 | 0 | 193K |
| Common Stock Repurchased | 0 | 0 | 0 | (244K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 213.79M | (1.17M) | (76K) | (5.52M) | (9.11M) |
| Financing Cash Flow | 332.26M | (1.08M) | (76K) | (5.76M) | (8.91M) |
| Effect of Forex Changes | 10.97M | (4.29M) | (66K) | (80K) | (339K) |
| Net Change in Cash | (4.69M) | 36.84M | (15.4M) | (9.37M) | 11.59M |
| Free Cash Flow | (16.42M) | (37.86M) | (34.46M) | (35.51M) | (59.92M) |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.